Gamma Knife Radiosurgery-Based Combination Treatment Strategies Improve Survival in Patients With Central Nervous System Metastases From Epithelial Ovarian Cancer: A Retrospective Analysis of Two Academic Institutions in Korea and Taiwan

Yen-Ling Lai, Jun-Hyeok Kang, Che-Yu Hsu, Jung-Il Lee, Wen‐Fang Cheng, Yu‐Li Chen, Yoo-Young LeeFrontiers in Oncology 2021 · DOI

Abstract

Central nervous system (CNS) metastases from epithelial ovarian cancer (EOC) are rare, occurring in approximately 1–2% of patients. This retrospective study of 94 patients from two major academic institutions in Korea and Taiwan investigated clinico-pathological prognostic factors and compared treatment outcomes. Key findings indicate that serous histology, absence of progressive disease at CNS diagnosis, and CNS involvement occurring after the first disease relapse are associated with significantly improved survival. Most importantly, Gamma Knife Radiosurgery (GKS)-based combination treatments provided a substantial survival benefit, particularly for patients whose CNS metastases were not part of their initial disease recurrence.

Introduction

Epithelial ovarian cancer (EOC) typically spreads within the peritoneal cavity. Metastasis to the central nervous system (brain or spinal cord) is an infrequent but devastating event, often associated with a poor prognosis. Historically, Whole Brain Radiation Therapy (WBRT) was the mainstay of treatment; however, its efficacy is limited by poor local control and significant neurocognitive side effects. Stereotactic radiosurgery, specifically Gamma Knife Radiosurgery (GKS), has emerged as a precise alternative that delivers high-dose radiation with sub-millimeter accuracy. However, its role in combination with other modalities for EOC patients has lacked multi-institutional validation until now.

Methods and Patient Assessment

The study retrospectively reviewed 6,300 EOC cases treated between 2000 and 2020 at Samsung Medical Center (Korea) and National Taiwan University Hospital (Taiwan). Ninety-four patients with CNS metastases were identified, representing an incidence rate of 1.49%. Patients were categorized into four treatment groups: RT only (conventional radiation), RT-based combination, GKS only, and GKS-based combination (GKS plus surgery, chemotherapy, or conventional RT).

Clinical assessment for GKS-based strategies followed specific criteria, including life expectancy, performance status, and tumor burden, as outlined in the clinical practice workflow.

Figure 1: Clinical assessment workflow for GKS-based treatment strategies in patients with CNS metastases from EOC.

Key Results

The median survival after CNS metastasis diagnosis across the entire cohort was 11.9 months. Several factors were identified as significant predictors of survival:

  • Histology: Patients with serous histological types had a significantly lower risk of death (Hazard Ratio [HR]: 0.49) compared to non-serous types.
  • Relapse Timing: Patients whose CNS involvement occurred after their first disease relapse had better survival outcomes, suggesting that early CNS spread may indicate a more aggressive phenotype.
  • Treatment Efficacy: GKS-based combination therapy significantly reduced the risk of death (HR: 0.59, p < 0.001) and achieved the highest therapeutic response rate (80%).
Figure 2: Kaplan-Meier survival curves illustrating the impact of (A) histology, (B) disease progression status, (C) timing of CNS relapse, and (D) treatment modality on overall survival.

In a notable subgroup analysis, patients whose CNS involvement was not the first recurrence and who received GKS-based combination therapy achieved a median survival of 32.9 months, compared to only 3.1 months for those receiving conventional RT alone.

Discussion and Conclusion

The timing of CNS metastasis appears to be a critical indicator of tumor biology. While "early" CNS spread (at first relapse) reflects a treatment-resistant phenotype, patients with later CNS involvement benefit significantly from the aggressive local control provided by GKS combined with systemic or surgical interventions.

GKS-based treatments resulted in the longest CNS recurrence-free intervals (9.7 months), suggesting that superior local control in the brain directly translates to extended overall survival. These findings support the use of GKS-based combination strategies as a preferred approach for eligible EOC patients with CNS metastases to maximize both survival and quality of life.

Summary updated

Abstract

Central nervous system (CNS) metastases from epithelial ovarian cancer (EOC) are rare. We investigated the clinico-pathological prognostic factors of patients with CNS metastases from EOC and compared the outcomes of various treatment modalities. We retrospectively reviewed the records of patients with CNS metastases from EOC between 2000 and 2020. Information on the clinical and pathological characteristics, treatment, and outcomes of these patients was retrieved from Samsung Medical Center and National Taiwan University Hospital. A total of 94 patients with CNS metastases were identified among 6,300 cases of EOC, resulting in an incidence of 1.49%. Serous histological type [hazard ratio (HR): 0.49 (95% confidence interval [CI] 0.25-0.95), <i>p</i>=0.03], progressive disease [HR: 2.29 (95% CI 1.16-4.54), <i>p</i>=0.01], CNS involvement in first disease relapse [HR: 0.36 (95% CI 0.18-0.70), <i>p</i>=0.002], and gamma knife radiosurgery (GKS)-based combination treatment for EOC patients with CNS lesions [HR: 0.59 (95% CI 0.44-0.79), <i>p</i><0.001] significantly impacted survival after diagnosis of CNS metastases. In a subgroup analysis, superior survival was observed in patients with CNS involvement not in first tumor recurrence who underwent GKS-based combination therapeutic regimens. The survival benefit of GKS-based treatment was not significant in patients with CNS involvement in first disease relapse, but a trend for longer survival was still observed. In conclusion, GKS-based combination treatment can be considered for the treatment of EOC patients with CNS metastases. The patients with CNS involvement not in first disease relapse could significantly benefit from GKS-based combination strategies.
BibTeX
@inproceedings{lai2021gamma,
  author = {Yen-Ling Lai and Jun-Hyeok Kang and Che-Yu Hsu and Jung-Il Lee and Wen‐Fang Cheng and Yu‐Li Chen and Yoo-Young Lee},
  title = {{Gamma Knife Radiosurgery-Based Combination Treatment Strategies Improve Survival in Patients With Central Nervous System Metastases From Epithelial Ovarian Cancer: A Retrospective Analysis of Two Academic Institutions in Korea and Taiwan}},
  booktitle = {Frontiers in Oncology},
  year = {2021},
  doi = {10.3389/fonc.2021.719936},
}
Figure